Moreover, loss of GABARAP compromises immunogenic cell death in multiple myeloma, reducing therapy efficacy (58), while in lung cancer, activation of a GABARAP-NIX axis induces selective mitophagy and radiosensitization (59). Here, GABARAP is linked to plasma cell myeloma.